
Dr Simon Best joins Aquapharm as chief executive
pharmafile | April 13, 2010 | Appointment | Research and Development | Aquapharm, Aquapharm Biodiscovery, appointment, research and development
Aquapharm has appointed Dr Simon Best (pictured) chief executive in a move that sees the Scottish marine biotechnology company’s current head and founder Andrew Mearns Spragg move to a new role as chief technical officer.
Dr Best has held previous positions as chief executive of Roslin BioMed, and chairman of Ardana and the UK BioIndustry Association.
He is a visiting professor at the University of Edinburgh and remains the chair of the BioQuarter Commercialisation Board.
His predecessor in the role Andrew Mearns Spragg said: “I would like to welcome Simon to Aquapharm, a company for which I have endless passion, having founded and developed it over the past 10 years.”
Best’s appointment comes as Aquapharm closes a £4.2 million investment from existing investors Aescap Venture, Tate & Lyle Ventures, Highlands and Islands Enterprise and NESTA.
The additional finance will be used towards the further development and commercialisation of Aquapharm’s product portfolio produced from over 7,250 marine micro-organisms.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






